Up 17% today  on completion of instituional placement and opening of retail placement. 

MACH7 COMPLETES INSTITUTIONAL ENTITLEMENT OFFER AND PLACEMENT WITH STRONG INVESTOR SUPPORT Highlights • Mach7 raises $23.4M (34.4M shares) under Placement and Institutional Entitlement Offer • Mach7 will seek to raise $11.4M (16.8M shares) pursuant to the fully underwritten Retail Entitlement Offer • All 51.2M shares will be issued at A$0.68 per share • Total funds of $34.8M will be used towards the acquisition of Client Outlook Inc. Melbourne, Australia; 12 June 2020: Mach7 Technologies Limited (“Mach7” or the “Company”) (ASX:M7T), a company specialising in innovative medical imaging data management solutions for healthcare providers, today announced it has successfully completed the institutional placement (Placement) and the institutional component of its entitlement offer (Institutional Entitlement Offer) announced to the ASX on Wednesday, 10 June 2020. Funds raised from the capital raising together with the Company’s existing cash reserves will be used to fund the purchase of Client Outlook Inc. as announced to market on 10 June 2020. Mike Lampron, CEO, said: “I am delighted by the strong demand for the capital raise so far. This highlights shareholder commitment to Mach7, from our existing shareholders and from new shareholders which we welcome to our register. Mach7 is continuing a market disruptive, high growth journey, which has now been enhanced by our acquisition of Client Outlook. We are excited by our growth potential and the immediate opportunities to improve patient outcomes and service delivery for our healthcare customers.” Placement and Institutional Entitlement Offer The Placement and Institutional Entitlement Offer raised $3.7 million and $19.7 million respectively, a total of $23.4 million. The Company will progress the planned Retail Entitlement Offer to raise a further $11.4 million, taking the total capital raise to $34.8 million. The Company will issue 5.4 million and 29.0 million shares under the Placement and Institutional Entitlement Offer respectively (New Shares), with all New Shares being issued at a fixed price of A$0.68 per share (Offer Price). This Offer Price represents a 13.9% discount to the last traded price of $0.79 on 9 June 2020, a 9.6% discount to the 5-day VWAP of $0.7524 up to 9 June 2020, and an 11.2% discount to the TERP1 of $0.7659. The New Shares issued will rank equally with existing Mach7 ordinary shares on issue. ASX Announcement Placement Shares issued represent 3% of issued capital (prior to the Entitlement Offer) and will be issued using ASX Listing Rule 7.1 (58,500 shares) and 7.1A (5,371,202 shares) capacity available to the Company. Settlement of the Placement and Institutional Entitlement Offer is expected to occur on Wednesday, 17 June 2020 with allotment of the New Shares expected to occur on Thursday, 18 June 2020. Morgans Corporate Limited has solely managed, and fully underwritten, both the Placement and the Institutional Entitlement Offer. Retail Entitlement Offer The Company will seek to raise A$11.4 million pursuant to the retail component of the Entitlement Offer (Retail Entitlement Offer). Eligible retail shareholders, with a registered address in Australia or New Zealand, are invited to subscribe for 1 New Share for every 4 shares they hold as at 7.00pm (AEST) on Friday, 12 June 2020 (Record Date), at an offer price of A$0.68 per share. The Retail Entitlement Offer is fully underwritten by Morgans Corporate Limited. The Retail Entitlement Offer will open on Wednesday 17 June 2020 and close at 5.00pm (AEST) on Friday 26 June 2020. Eligible retail shareholders who take up their entitlement in full will also be offered the opportunity to subscribe for additional New Shares, up to a maximum of 50% of their entitlement under an oversubscription facility, but only to the extent that there is a shortfall under the Retail Entitlement Offer (Shortfall Facility) and at the Board’s absolute discretion. Entitlements cannot be traded on the ASX or transferred. Eligible shareholders who do not take up their entitlement under the Entitlement Offer in full or in part, will not receive any value in respect to those Entitlements not taken up. Further details about the Retail Entitlement Offer will be set out in the retail offer booklet, which the Company expects to lodge with the ASX and dispatch on Wednesday, 17 June 2020.

This is one of the first stocks i ever bought - back in mid 2018 @ $0.31. I heard about it on a podcast, read some company reports and liked what i saw. 6 months later I had lost 50% of my investment in it. I wish i could say i bought some more but i didn't but i didn't sell either. Fast forward to 2020 and my return is currently over 100% AND the fundermentals of this company are very sound. Ok i have other shares that are still below their March 2020 lows but there is something very satisfy about backing yourself onto a winner.

Here's hope of more upside!

Wilsons Rapid Insights Conference 28 May 2020 presentation.

http://www.aspecthuntley.com.au/docserver/02239269.pdf?fileid=02239269&datedir=20200528&edt=MjAyMC0wNS0yOCsxNzoxODo1Mis0ODArMTY5NjIyK2FuZHJld3dlc3QrcmVkaXJlY3QraHR0cDovL3d3dy5hc3BlY3RodW50bGV5LmNvbS5hdS9pbWFnZXNpZ25hbC9lcnJvcnBhZ2VzL3BkZnRpbWVvdXQuaHRtbCtodHRwOi8vd3d3LmFzcGVjdGh1bnRsZXkuY29tLmF1L2ltYWdlc2lnbmFsL2Vycm9ycGFnZXMvcGRmZGVsYXllZC5qc3A=

I like this company more with everything i read

I hold in Strawman and Personel portfolio

I recently contacted M7T's Investor relations to ask about when the full year results will be released (see below). An interesting comment though about the "growing interest  in the company"

My apologies for the delay in responding. Historically the full year results have been released during the final week of August.

I can’t provide a provisional date as yet with the timing of Board meetings and audit involvement not 100% finalised. Until a date is published assume the final week of August. We will be publishing the date in advance given the growing interest in the company and looking to host a results conference call.

Melbourne, Australia; 11 March 2020: Mach7 Technologies Limited (“Mach7” or the “Company”) (ASX:M7T), a company specialising in innovative medical imaging data management solutions for healthcare providers, today announced the completion or ‘go-live’ of a Picture Archiving and Communication System (PACS) modernisation project for Sentara Healthcare. The PACS is powered by Mach7’s Enterprise Imaging Platform (VNA) and Diagnostic Studio in conjunction with Client Outlook’s eUnity diagnostic viewer. The project marks the first cloud-based deployment of the complete Mach7 solution at a customer site. The solution is a public cloud deployment utilizing the Microsoft Azure framework, covering more than two million images per year across the Sentara Healthcare network. In addition to storing data for Sentara’s radiology departments, the Mach7 VNA also stores images and image data for their cardiology departments, which provides a greater degree of infrastructure consolidation and integration. This go-live milestone triggers a new Mach7 software subscription license that will generate $850k of recurring subscription revenue per annum for Mach7, of which approximately 50% is additional revenue and 50% is conversion of a previous annual support and maintenance agreement. Trent Conwell, Sentara Healthcare’s IT Director, said, “As organizations are making decisions on how best to deliver IT infrastructure in a clinically and fiscally responsible way it is imperative to evaluate each software vendor’s infrastructure capabilities. Sentara partnered with Mach7 to provide a standardized diagnostic imaging solution that provides the infrastructure flexibility that we needed. Moving to a centralized cloud infrastructure means the days of keeping up to seven copies of diagnostic studies are gone. All studies are centralized and available diagnostically to interpreting physicians across the Sentara enterprise.” Mike Lampron, CEO of Mach7 Technologies, said, “Mach7 is excited to announce the successful go-live of Sentara’s PACS Modernization project. Our vendor-neutral solution will give Sentara unparalleled flexibility and cost savings, with a foundation they will be able to build on for years to ASX Announcement come. We are confident the joint Mach7-Client Outlook solution will meet the needs of their organization and we look forward to our continued partnership.”